PE20170503A1 - Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso - Google Patents

Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso

Info

Publication number
PE20170503A1
PE20170503A1 PE2017000128A PE2017000128A PE20170503A1 PE 20170503 A1 PE20170503 A1 PE 20170503A1 PE 2017000128 A PE2017000128 A PE 2017000128A PE 2017000128 A PE2017000128 A PE 2017000128A PE 20170503 A1 PE20170503 A1 PE 20170503A1
Authority
PE
Peru
Prior art keywords
interleukin
polypeptide
alpha receptor
methods
fusion proteins
Prior art date
Application number
PE2017000128A
Other languages
English (en)
Inventor
Thomas Malek
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170503(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Miami filed Critical Univ Miami
Publication of PE20170503A1 publication Critical patent/PE20170503A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)

Abstract

Se refiere a una proteina de fusion que comprende: (a) un primer polipeptido que comprende interleucina-2 (IL-2) o una variante funcional o fragmento de la misma; y (b) un segundo polipeptido, fusionado dentro del marco de lectura al primer polipeptido, el segundo polipeptido comprende un dominio extracelular de receptor de interleucina 2 alfa (IL-2R?) o una variante funcional o fragmento del mismo; en donde la proteina de fusion tiene actividad IL-2. Dichas proteinas modulan la respuesta inmune siendo utiles en el tratamiento de cancer y VIH/AID
PE2017000128A 2014-08-06 2015-08-05 Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso PE20170503A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06

Publications (1)

Publication Number Publication Date
PE20170503A1 true PE20170503A1 (es) 2017-05-11

Family

ID=53836871

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000128A PE20170503A1 (es) 2014-08-06 2015-08-05 Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso

Country Status (21)

Country Link
US (2) US20170233448A1 (es)
EP (1) EP3177307A1 (es)
JP (3) JP6723982B2 (es)
KR (1) KR102653758B1 (es)
CN (2) CN107074967B (es)
AU (3) AU2015301071C1 (es)
BR (1) BR112017001940A2 (es)
CA (1) CA2957273C (es)
CL (1) CL2017000284A1 (es)
CO (1) CO2017002166A2 (es)
EA (2) EA202091342A3 (es)
IL (2) IL250007B (es)
MA (2) MA40721A (es)
MX (1) MX2017001062A (es)
MY (1) MY180831A (es)
PE (1) PE20170503A1 (es)
PH (1) PH12017500042A1 (es)
SA (1) SA517380842B1 (es)
SG (2) SG10201913695PA (es)
TN (1) TN2017000020A1 (es)
WO (1) WO2016022671A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
MX370283B (es) 2014-02-06 2019-12-09 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas.
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN109689694B (zh) * 2016-05-19 2022-11-22 通用医疗公司 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
KR20190057113A (ko) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11780899B2 (en) 2017-12-06 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to IL-2
WO2019183389A1 (en) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
MX2020009975A (es) * 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
WO2020187848A1 (en) * 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036A (zh) 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
CN114555110A (zh) * 2019-10-18 2022-05-27 奥克梅斯制药爱尔兰有限公司 与免疫检查点抑制剂组合的免疫调节性il-2剂
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
WO2023154894A2 (en) * 2022-02-11 2023-08-17 Alkermes Pharma Ireland Limited Compositions and methods for cancer immunotherapy
WO2023159135A2 (en) * 2022-02-16 2023-08-24 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235514T1 (de) * 1994-12-28 2003-04-15 Univ Kentucky Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
CN1596311A (zh) * 2001-09-28 2005-03-16 株式会社载体研究所 编码表位结合型β2m且感染哺乳动物细胞的病毒载体及其应用
CA2608474C (en) * 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
JP2017523789A (ja) 2017-08-24
SG10201913695PA (en) 2020-03-30
CA2957273A1 (en) 2016-02-11
TN2017000020A1 (en) 2018-07-04
WO2016022671A1 (en) 2016-02-11
MA40721A (fr) 2017-06-13
MA40094A1 (fr) 2021-09-30
EA201790063A1 (ru) 2017-06-30
KR102653758B1 (ko) 2024-04-04
KR20170030646A (ko) 2017-03-17
EA202091342A3 (ru) 2020-12-30
IL250007B (en) 2020-07-30
AU2015301071C1 (en) 2020-07-02
AU2015301071A1 (en) 2017-02-02
BR112017001940A2 (pt) 2017-11-28
PH12017500042A1 (en) 2017-05-22
EP3177307A1 (en) 2017-06-14
MX2017001062A (es) 2017-07-14
CN107074967A (zh) 2017-08-18
IL250007A0 (en) 2017-03-30
US20170233448A1 (en) 2017-08-17
AU2022204034A1 (en) 2022-07-14
JP2023099045A (ja) 2023-07-11
SA517380842B1 (ar) 2021-12-26
JP7272663B2 (ja) 2023-05-12
MY180831A (en) 2020-12-10
US20230079120A1 (en) 2023-03-16
EA202091342A2 (ru) 2020-11-30
CN113912737A (zh) 2022-01-11
AU2015301071B2 (en) 2020-03-05
CO2017002166A2 (es) 2017-05-19
AU2020203352A1 (en) 2020-07-02
CA2957273C (en) 2023-03-14
CN107074967B (zh) 2021-06-08
IL275944A (en) 2020-08-31
SG11201700706WA (en) 2017-02-27
JP6723982B2 (ja) 2020-07-15
IL275944B (en) 2022-02-01
AU2020203352B2 (en) 2022-03-10
EA035956B1 (ru) 2020-09-04
MA40094B1 (fr) 2022-05-31
JP2021000084A (ja) 2021-01-07
CL2017000284A1 (es) 2017-11-17

Similar Documents

Publication Publication Date Title
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CL2018000358A1 (es) Proteínas de fusión de gitrl y usos de las mismas
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12018502213A1 (en) Anti-myostatin antibodies and methods of use
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
BR112019014986A2 (pt) anticorpo que alveja bcma e uso do mesmo
CL2020002477A1 (es) Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
EA202092327A1 (ru) Варианты lfa3 и их композиции и применение
AR099080A1 (es) Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas